Review



human jurkat cell line  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    ATCC human jurkat cell line
    Human Jurkat Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 339 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human jurkat cell line/product/ATCC
    Average 95 stars, based on 339 article reviews
    human jurkat cell line - by Bioz Stars, 2026-03
    95/100 stars

    Images



    Similar Products

    95
    ATCC human jurkat cell line
    Human Jurkat Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human jurkat cell line/product/ATCC
    Average 95 stars, based on 1 article reviews
    human jurkat cell line - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    99
    ATCC human jurkat t cells
    Human Jurkat T Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human jurkat t cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    human jurkat t cells - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    94
    CLS Cell Lines Service GmbH human t lymphoblast
    Human T Lymphoblast, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human t lymphoblast/product/CLS Cell Lines Service GmbH
    Average 94 stars, based on 1 article reviews
    human t lymphoblast - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    99
    ATCC jurkat immortalized human t lymphocytes
    Jurkat Immortalized Human T Lymphocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jurkat immortalized human t lymphocytes/product/ATCC
    Average 99 stars, based on 1 article reviews
    jurkat immortalized human t lymphocytes - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC human jurkat t leukemia
    Human Jurkat T Leukemia, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human jurkat t leukemia/product/ATCC
    Average 99 stars, based on 1 article reviews
    human jurkat t leukemia - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    95
    Genecopoeia cas9
    Cell viabilities of Jurkat wild-type (Jurkat WT) cells and Jurkat cells stably expressing <t>Cas9</t> (Jurkat-Cas9) treated with different concentrations of FTY720. (A) 24-hour and (B) 48-hour treatment timepoint. The % of cell viability was calculated in comparison to the non-treated control (Control). Data are expressed as mean ± S.D. (error bars) from 2 independent experiments. Control = non-treated control; DMSO = vehicle control
    Cas9, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cas9/product/Genecopoeia
    Average 95 stars, based on 1 article reviews
    cas9 - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    99
    ATCC human jurkat clone e6 1
    Timed delivery of fluorescently tagged dextran to <t>Jurkat</t> cells (A) Schematic of typical and timed delivery experiments performed. In a typical experiment, target cells are premixed with fluorescent cargo (fluorescein isothiocyanate dextran, FITC-Dex). In timed delivery experiments, cells are treated in delivery buffer without cargo while FITC-Dex is added at a later time point. Flow cytometry is performed within 2 h of treatment to determine delivery efficiency (percentage of cells positive for FITC). (B) Filtroporation of Jurkat cells with FITC-Dex; cargo was either premixed or added at the specified time point. Controls were untreated, mock filtroporated (FP without cargo) or incubated with FITC-Dex without FP (Incub Ctrl). (C) Viabilities determined by 4′,6-diamidino-2-phenylindole (DAPI) staining at the time of flow cytometry after FP experiments. (D) Nucleofection (EP) of Jurkat cells with FITC-Dex; cargo was either premixed or added at the specified time point. Controls were untreated or mock nucleofected (EP without cargo). (E) Viabilities determined by 4′,6-diamidino-2-phenylindole (DAPI) staining at the time of flow cytometry after EP experiments. Data are shown for n ≥ 2 independent experiments. See also and . Data are shown as mean ± standard deviation.
    Human Jurkat Clone E6 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human jurkat clone e6 1/product/ATCC
    Average 99 stars, based on 1 article reviews
    human jurkat clone e6 1 - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    95
    ATCC jurkat human leukemic t cell line
    Timed delivery of fluorescently tagged dextran to <t>Jurkat</t> cells (A) Schematic of typical and timed delivery experiments performed. In a typical experiment, target cells are premixed with fluorescent cargo (fluorescein isothiocyanate dextran, FITC-Dex). In timed delivery experiments, cells are treated in delivery buffer without cargo while FITC-Dex is added at a later time point. Flow cytometry is performed within 2 h of treatment to determine delivery efficiency (percentage of cells positive for FITC). (B) Filtroporation of Jurkat cells with FITC-Dex; cargo was either premixed or added at the specified time point. Controls were untreated, mock filtroporated (FP without cargo) or incubated with FITC-Dex without FP (Incub Ctrl). (C) Viabilities determined by 4′,6-diamidino-2-phenylindole (DAPI) staining at the time of flow cytometry after FP experiments. (D) Nucleofection (EP) of Jurkat cells with FITC-Dex; cargo was either premixed or added at the specified time point. Controls were untreated or mock nucleofected (EP without cargo). (E) Viabilities determined by 4′,6-diamidino-2-phenylindole (DAPI) staining at the time of flow cytometry after EP experiments. Data are shown for n ≥ 2 independent experiments. See also and . Data are shown as mean ± standard deviation.
    Jurkat Human Leukemic T Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jurkat human leukemic t cell line/product/ATCC
    Average 95 stars, based on 1 article reviews
    jurkat human leukemic t cell line - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    98
    ATCC jurkat e6 1 human t cell leukemia
    Timed delivery of fluorescently tagged dextran to <t>Jurkat</t> cells (A) Schematic of typical and timed delivery experiments performed. In a typical experiment, target cells are premixed with fluorescent cargo (fluorescein isothiocyanate dextran, FITC-Dex). In timed delivery experiments, cells are treated in delivery buffer without cargo while FITC-Dex is added at a later time point. Flow cytometry is performed within 2 h of treatment to determine delivery efficiency (percentage of cells positive for FITC). (B) Filtroporation of Jurkat cells with FITC-Dex; cargo was either premixed or added at the specified time point. Controls were untreated, mock filtroporated (FP without cargo) or incubated with FITC-Dex without FP (Incub Ctrl). (C) Viabilities determined by 4′,6-diamidino-2-phenylindole (DAPI) staining at the time of flow cytometry after FP experiments. (D) Nucleofection (EP) of Jurkat cells with FITC-Dex; cargo was either premixed or added at the specified time point. Controls were untreated or mock nucleofected (EP without cargo). (E) Viabilities determined by 4′,6-diamidino-2-phenylindole (DAPI) staining at the time of flow cytometry after EP experiments. Data are shown for n ≥ 2 independent experiments. See also and . Data are shown as mean ± standard deviation.
    Jurkat E6 1 Human T Cell Leukemia, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jurkat e6 1 human t cell leukemia/product/ATCC
    Average 98 stars, based on 1 article reviews
    jurkat e6 1 human t cell leukemia - by Bioz Stars, 2026-03
    98/100 stars
      Buy from Supplier

    Image Search Results


    Cell viabilities of Jurkat wild-type (Jurkat WT) cells and Jurkat cells stably expressing Cas9 (Jurkat-Cas9) treated with different concentrations of FTY720. (A) 24-hour and (B) 48-hour treatment timepoint. The % of cell viability was calculated in comparison to the non-treated control (Control). Data are expressed as mean ± S.D. (error bars) from 2 independent experiments. Control = non-treated control; DMSO = vehicle control

    Journal: BMC Research Notes

    Article Title: A genome-wide CRISPR/Cas9 screen reveals novel positive regulators of FTY720 sensitivity in acute lymphoblastic leukemia cells

    doi: 10.1186/s13104-026-07654-4

    Figure Lengend Snippet: Cell viabilities of Jurkat wild-type (Jurkat WT) cells and Jurkat cells stably expressing Cas9 (Jurkat-Cas9) treated with different concentrations of FTY720. (A) 24-hour and (B) 48-hour treatment timepoint. The % of cell viability was calculated in comparison to the non-treated control (Control). Data are expressed as mean ± S.D. (error bars) from 2 independent experiments. Control = non-treated control; DMSO = vehicle control

    Article Snippet: Jurkat cells stably expressing Cas9 (Genecopoeia, Rockville, MD, catalog no. SL555) were grown following the manufacturer’s protocol.

    Techniques: Stable Transfection, Expressing, Comparison, Control

    Genome-wide CRISPR/Cas9 screen for positive regulators of the FTY720 compared to DMSO (vehicle control) samples. (A) Ranking of positively selected sgRNAs of genes from the MAGeCK-VISPR analysis. The x-axis indicates the positive ranking of individual genes, and the y-axis indicates the values of the corresponding robust ranking aggregation (RRA) score. The top 10 sgRNAs of genes are highlighted and labeled. Two independent screens were performed. (B-K) The read counts (y-axis) and samples (DMSO vs . FTY720 treatment) are shown for the positively selected sgRNAs of genes (B) ZNF575 , (C) GPX3 , (D) FBXL15 , (E) DNAJB5 , (F) UBE2D1 , (G) ATXN7 , (H) C6orf201 , (I) RIC8A , (J) RAB13 and (K) C10orf12 . RRA = robust ranking aggregation score, sgRNA = single-guide RNAs

    Journal: BMC Research Notes

    Article Title: A genome-wide CRISPR/Cas9 screen reveals novel positive regulators of FTY720 sensitivity in acute lymphoblastic leukemia cells

    doi: 10.1186/s13104-026-07654-4

    Figure Lengend Snippet: Genome-wide CRISPR/Cas9 screen for positive regulators of the FTY720 compared to DMSO (vehicle control) samples. (A) Ranking of positively selected sgRNAs of genes from the MAGeCK-VISPR analysis. The x-axis indicates the positive ranking of individual genes, and the y-axis indicates the values of the corresponding robust ranking aggregation (RRA) score. The top 10 sgRNAs of genes are highlighted and labeled. Two independent screens were performed. (B-K) The read counts (y-axis) and samples (DMSO vs . FTY720 treatment) are shown for the positively selected sgRNAs of genes (B) ZNF575 , (C) GPX3 , (D) FBXL15 , (E) DNAJB5 , (F) UBE2D1 , (G) ATXN7 , (H) C6orf201 , (I) RIC8A , (J) RAB13 and (K) C10orf12 . RRA = robust ranking aggregation score, sgRNA = single-guide RNAs

    Article Snippet: Jurkat cells stably expressing Cas9 (Genecopoeia, Rockville, MD, catalog no. SL555) were grown following the manufacturer’s protocol.

    Techniques: Genome Wide, CRISPR, Control, Labeling

    Timed delivery of fluorescently tagged dextran to Jurkat cells (A) Schematic of typical and timed delivery experiments performed. In a typical experiment, target cells are premixed with fluorescent cargo (fluorescein isothiocyanate dextran, FITC-Dex). In timed delivery experiments, cells are treated in delivery buffer without cargo while FITC-Dex is added at a later time point. Flow cytometry is performed within 2 h of treatment to determine delivery efficiency (percentage of cells positive for FITC). (B) Filtroporation of Jurkat cells with FITC-Dex; cargo was either premixed or added at the specified time point. Controls were untreated, mock filtroporated (FP without cargo) or incubated with FITC-Dex without FP (Incub Ctrl). (C) Viabilities determined by 4′,6-diamidino-2-phenylindole (DAPI) staining at the time of flow cytometry after FP experiments. (D) Nucleofection (EP) of Jurkat cells with FITC-Dex; cargo was either premixed or added at the specified time point. Controls were untreated or mock nucleofected (EP without cargo). (E) Viabilities determined by 4′,6-diamidino-2-phenylindole (DAPI) staining at the time of flow cytometry after EP experiments. Data are shown for n ≥ 2 independent experiments. See also and . Data are shown as mean ± standard deviation.

    Journal: iScience

    Article Title: Membrane repair following filtroporation-induced cell permeabilization

    doi: 10.1016/j.isci.2025.114317

    Figure Lengend Snippet: Timed delivery of fluorescently tagged dextran to Jurkat cells (A) Schematic of typical and timed delivery experiments performed. In a typical experiment, target cells are premixed with fluorescent cargo (fluorescein isothiocyanate dextran, FITC-Dex). In timed delivery experiments, cells are treated in delivery buffer without cargo while FITC-Dex is added at a later time point. Flow cytometry is performed within 2 h of treatment to determine delivery efficiency (percentage of cells positive for FITC). (B) Filtroporation of Jurkat cells with FITC-Dex; cargo was either premixed or added at the specified time point. Controls were untreated, mock filtroporated (FP without cargo) or incubated with FITC-Dex without FP (Incub Ctrl). (C) Viabilities determined by 4′,6-diamidino-2-phenylindole (DAPI) staining at the time of flow cytometry after FP experiments. (D) Nucleofection (EP) of Jurkat cells with FITC-Dex; cargo was either premixed or added at the specified time point. Controls were untreated or mock nucleofected (EP without cargo). (E) Viabilities determined by 4′,6-diamidino-2-phenylindole (DAPI) staining at the time of flow cytometry after EP experiments. Data are shown for n ≥ 2 independent experiments. See also and . Data are shown as mean ± standard deviation.

    Article Snippet: Human: Jurkat Clone E6-1 , ATCC , TIB-152.

    Techniques: Flow Cytometry, Incubation, Staining, Standard Deviation

    Calcium concentration is critical during transfection by filtroporation (A) Delivery efficiency determined by flow cytometry within 2 h of filtroporation of Jurkat or CD34 + bone marrow derived human hematopoietic stem and progenitor cells (HSPCs) with fluorescein isothiocyanate (FITC)-tagged dextran (FITC-Dex) in cell media with low calcium (Roswell Park Memorial Institute, RPMI), FP-Dex (0.42 mM Ca 2+ ), or with additional 1 mM CaCl 2 added, FP-Dex (1.42 mM Ca 2+ ). Controls were either untreated, filtroporated without cargo (FP-Mock), or incubated in FITC-Dex without FP (Incub-Dex). (B) Viabilities of filtroporated Jurkat cells determined by 4′,6-diamidino-2-phenylindole (DAPI) at the time of flow cytometry. Cells were also transfected in phosphate buffered saline (PBS) as delivery buffer (FP-Dex-PBS). (C) Jurkat cells were filtroporated with green fluorescent protein (GFP)-encoding plasmid (pGFP) in different delivery buffers: RPMI, minimum essential media (MEM) containing no calcium, or a 1:1 mixture of RPMI and MEM (0.21 mM Ca 2+ ). Media was introduced at the bottom of the collection tube such that cells subjected to filtroporation fell into either RPMI, MEM or RPMI:MEM 1:1 media. Results are displayed for cells at 24 h post-filtroporation (timepoint with highest expression). (D) Cell counts at 24–72 h post-filtroporation performed with acridine orange/propidium iodide fluorescent staining. (E) Percentage of GFP-positive cells (left) and cell viability (right) determined by DAPI staining at the time of flow cytometry. Mock RPMI/MEM: cells filtroporated without cargo in RPMI or MEM; FP-RPMI-pGFP: cells subjected to FP in RPMI with pGFP cargo; FP-MEM-pGFP: cells subjected to FP in MEM with pGFP cargo; FP-MtR-pGFP: cells subjected to FP with pGFP cargo in MEM falling into RPMI media; FP-Premix-pGFP: cells subjected to FP with pGFP cargo in RPMI:MEM premixed media. Data are shown for n ≥ 2 independent experiments. (∗∗ p < 0.005, ∗∗∗ p < 0.001 and ∗∗∗∗ p < 0.0001). Data are shown as mean ± standard deviation.

    Journal: iScience

    Article Title: Membrane repair following filtroporation-induced cell permeabilization

    doi: 10.1016/j.isci.2025.114317

    Figure Lengend Snippet: Calcium concentration is critical during transfection by filtroporation (A) Delivery efficiency determined by flow cytometry within 2 h of filtroporation of Jurkat or CD34 + bone marrow derived human hematopoietic stem and progenitor cells (HSPCs) with fluorescein isothiocyanate (FITC)-tagged dextran (FITC-Dex) in cell media with low calcium (Roswell Park Memorial Institute, RPMI), FP-Dex (0.42 mM Ca 2+ ), or with additional 1 mM CaCl 2 added, FP-Dex (1.42 mM Ca 2+ ). Controls were either untreated, filtroporated without cargo (FP-Mock), or incubated in FITC-Dex without FP (Incub-Dex). (B) Viabilities of filtroporated Jurkat cells determined by 4′,6-diamidino-2-phenylindole (DAPI) at the time of flow cytometry. Cells were also transfected in phosphate buffered saline (PBS) as delivery buffer (FP-Dex-PBS). (C) Jurkat cells were filtroporated with green fluorescent protein (GFP)-encoding plasmid (pGFP) in different delivery buffers: RPMI, minimum essential media (MEM) containing no calcium, or a 1:1 mixture of RPMI and MEM (0.21 mM Ca 2+ ). Media was introduced at the bottom of the collection tube such that cells subjected to filtroporation fell into either RPMI, MEM or RPMI:MEM 1:1 media. Results are displayed for cells at 24 h post-filtroporation (timepoint with highest expression). (D) Cell counts at 24–72 h post-filtroporation performed with acridine orange/propidium iodide fluorescent staining. (E) Percentage of GFP-positive cells (left) and cell viability (right) determined by DAPI staining at the time of flow cytometry. Mock RPMI/MEM: cells filtroporated without cargo in RPMI or MEM; FP-RPMI-pGFP: cells subjected to FP in RPMI with pGFP cargo; FP-MEM-pGFP: cells subjected to FP in MEM with pGFP cargo; FP-MtR-pGFP: cells subjected to FP with pGFP cargo in MEM falling into RPMI media; FP-Premix-pGFP: cells subjected to FP with pGFP cargo in RPMI:MEM premixed media. Data are shown for n ≥ 2 independent experiments. (∗∗ p < 0.005, ∗∗∗ p < 0.001 and ∗∗∗∗ p < 0.0001). Data are shown as mean ± standard deviation.

    Article Snippet: Human: Jurkat Clone E6-1 , ATCC , TIB-152.

    Techniques: Concentration Assay, Transfection, Flow Cytometry, Derivative Assay, Incubation, Saline, Plasmid Preparation, Expressing, Staining, Standard Deviation

    SNAP23 and CHMP4B are involved in membrane repair immediately after filtroporation (A–H) Confocal images overlaying enhanced green fluorescent protein (eGFP) and 4′,6-diamino-2-phenylindole (DAPI) fluorescence channels for untreated and filtroporated Jurkat cells expressing (A,E) GRAF1-eGFP, (B,F) SNAP23-eGFP, and (C,G) CHMP4B-mCherry, with (D,H) free cytoplasmic eGFP as a negative control. (I–P) Quantification of foci per cell per image captured on confocal microscopy for the different cell lines with cells immediately fixed after filtroporation or at different time points (GRAF1-eGFP: I and M; SNAP23-eGFP: J and N; CHMP4B-mCherry: K and O; free cytoplasmic eGFP: L and P). (∗ p < 0.05, ∗∗ p < 0.005, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001). See also . Data are shown as mean ± standard deviation. Scale bars are 10 μm in panels A and E, and 5 μm in all other images.

    Journal: iScience

    Article Title: Membrane repair following filtroporation-induced cell permeabilization

    doi: 10.1016/j.isci.2025.114317

    Figure Lengend Snippet: SNAP23 and CHMP4B are involved in membrane repair immediately after filtroporation (A–H) Confocal images overlaying enhanced green fluorescent protein (eGFP) and 4′,6-diamino-2-phenylindole (DAPI) fluorescence channels for untreated and filtroporated Jurkat cells expressing (A,E) GRAF1-eGFP, (B,F) SNAP23-eGFP, and (C,G) CHMP4B-mCherry, with (D,H) free cytoplasmic eGFP as a negative control. (I–P) Quantification of foci per cell per image captured on confocal microscopy for the different cell lines with cells immediately fixed after filtroporation or at different time points (GRAF1-eGFP: I and M; SNAP23-eGFP: J and N; CHMP4B-mCherry: K and O; free cytoplasmic eGFP: L and P). (∗ p < 0.05, ∗∗ p < 0.005, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001). See also . Data are shown as mean ± standard deviation. Scale bars are 10 μm in panels A and E, and 5 μm in all other images.

    Article Snippet: Human: Jurkat Clone E6-1 , ATCC , TIB-152.

    Techniques: Membrane, Fluorescence, Expressing, Negative Control, Confocal Microscopy, Standard Deviation